Top stories in infectious disease: Updates in COVID-19, highlights from CROI

The top story in infectious disease last week was about Italy’s COVID-19 containment and mitigation measures and how hospitals are dealing with the surge of cases.

Another top story was about how limited COVID-19 testing capacity is hindering laboratories from successfully identifying U.S. cases.

Read these and more of last week’s top stories in infectious disease below:

‘I stay at home’: Italy hardens emergency COVID-19 measures

TREVISO, Italy — Day after day, COVID-19 containment and mitigation measures become more stringent in Italy, while hospitals are under extraordinary pressure to meet the surge in cases. Read more.

Limited COVID-19 testing capacity has US physicians ‘flying blind’

Testing capacity issues for COVID-19 have hindered laboratories from effectively identifying cases of the virus in the United States since the beginning of the outbreak — leaving some experts concerned for the country’s ability to contain its spread. Read more.

‘Cure is possible’: London patient remains in HIV remission 1 year later

The London patient, whose case was first reported 1 year ago at CROI 2019, has remained in HIV-1 remission for 30 months, according to findings from CROI 2020. Read more.

Injectable HIV regimen demonstrates similar efficacy when administered monthly, bimonthly

The antiviral activity and safety of long-acting cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals) administered every 2 months was noninferior to administration of the combination every month among adults with HIV-1 infection, according to study results from the global phase 3 ATLAS-2M study presented during CROI 2020. Read more.

IMPAACT 2010 trial confirms recommendations for dolutegravir use in pregnancy

Dolutegravir and emtricitabine/tenofovir alafenamide fumarate may be the safest and most effective HIV treatment regimen for pregnant women, according to findings from CROI 2020. Read more.